Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2018-01-08 Regulatory Filings
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 8, 2018, by Titan Pharmaceuticals, Inc. The key content is the announcement of an updated corporate presentation attached as Exhibit 99.1. The document explicitly states that the presentation is being furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not considered "filed" for certain legal purposes. There is no substantive financial data or detailed report content within the document itself; it primarily serves as a notice of the presentation's availability. The document length is 3554 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, announcements of presentations or reports that are short and refer to attached materials should be classified as Regulatory Filings (RNS) rather than as the report or presentation itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-01-08 English
Regulatory Filings 2017
Regulatory Filings
2017-12-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a binding term sheet for licensing and commercialization rights), which is a typical subject of an 8-K filing. It includes details about the agreement terms, milestone payments, and regulatory updates but does not contain comprehensive financial statements or detailed financial performance data. The document is not an annual or quarterly report, audit report, or earnings release. It is not a proxy, voting result, or management change announcement. The primary focus is on a material contract and related business event. Therefore, the filing type corresponds to a Regulatory Filing (RNS) as a fallback category for SEC Form 8-K filings that do not fit other specific categories.
2017-11-28 English
FORM 10-Q
Interim / Quarterly Report Q3 2017
2017-11-09 English
Regulatory Filings 2017
Regulatory Filings
2017-11-09 English
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a letter to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to a securities registration filing, not a financial report or earnings release. The document is short (1506 characters) and is a formal request rather than a report or announcement of financial results. It does not contain financial data or detailed disclosures but is related to capital raising activities through a registration statement. Therefore, it fits best under Capital/Financing Update (CAP).
2017-11-07 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.